Characteristics and potential predictors of prematurely terminated interventional clinical trials for ovarian cancer in the ClinicalTrials.gov database
Many randomised clinical trials (RCT) do not reach their endpoint with about 25% being terminated for various reasons. This study used data from the Clinical Trials.gov website to discover whether this is true for ovarian cancer also.
The website records all clinical trials recruiting in the US and World-wide, a listing on this site does not require FDA or NIH approval. During the period 2003-2022 1420 RCTs for ovarian cancer were included.
Of these, 21% were terminated early. Mostly this was a result of logistic issues such as recruitment or funding. About 1/5th of the terminations was due to the intervention being non-effective.
The RCTs most likely to be terminated tended to be larger trials requiring big numbers of participants and were more likely when the trial was phase 2. A trial involving multiple large centres of care was most likely to be successfully completed.
No comments:
Post a Comment